Special Issue

Vascular Malformation: From Pathophysiology, Clinical Manifestations to Novel Therapeutic Approaches

Message from the Guest Editors

Arteriovenous malformations (AVMs) are active angiogenic lesions consisting of tangles of abnormal vessels shunting blood directly from arteries to veins without a true capillary bed. The mechanism of AVM formation is not fully understood. Recent studies identified somatic mutations in genes in RAS-MAPK pathway in sporadic bAVMs and peripheral AVMs. However, the significance of these genes in AVM development needs to be studied further. The existing treatment modalities for AVM have considerable adverse effects. With the advance of imaging techniques, more asymptomatic AVM patients will be diagnosed. The treatment of asymptomatic patients has become increasingly controversial because the natural history of these patients may be less morbid than invasive therapy. Therefore, uncovering AVM pathogenesis and identifying targets for the development of specific medical therapies are urgently needed. This Special Issue focuses on the research topic of molecular mechanisms underlying AVM development and progression, clinical management, and targets for the development of new therapies. We welcome both original research and review manuscripts.

Guest Editors

Dr. Hua Su

Center for Cerebrovascular Research, University of California, San Francisco, CA, USA

Dr. Li Ma

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Deadline for manuscript submissions

closed (31 January 2025)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/175492

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).